Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
BR0317284A - Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno - Google Patents
[go: Go Back, main page]

BR0317284A - Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno - Google Patents

Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno

Info

Publication number
BR0317284A
BR0317284A BR0317284-8A BR0317284A BR0317284A BR 0317284 A BR0317284 A BR 0317284A BR 0317284 A BR0317284 A BR 0317284A BR 0317284 A BR0317284 A BR 0317284A
Authority
BR
Brazil
Prior art keywords
protein kinase
activated protein
inhibitors
aminocyanopyridine
mitogen
Prior art date
Application number
BR0317284-8A
Other languages
English (en)
Inventor
David R Anderson
Nathan W Stehle
Stephen A Kolodziej
Emily J Reinhard
Len F Lee
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0317284A publication Critical patent/BR0317284A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"INIBIDORES AMINOCIANOPIRIDINA DE PROTEìNA QUINASE-2 ATIVADA COM PROTEìNA QUINASE ATIVADA COM MITóGENO". A presente invenção refere-se a compostos aminocianopiridina que são descritos, os quais podem inibir a proteína quinase-2 ativada com proteína quinase ativada com mitógeno. Composições farmacêuticas e kits que contêm esses compostos são também descritos.
BR0317284-8A 2002-12-12 2003-12-09 Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno BR0317284A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43284302P 2002-12-12 2002-12-12
PCT/US2003/038980 WO2004055015A1 (en) 2002-12-12 2003-12-09 Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2

Publications (1)

Publication Number Publication Date
BR0317284A true BR0317284A (pt) 2005-11-08

Family

ID=32595090

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317284-8A BR0317284A (pt) 2002-12-12 2003-12-09 Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno

Country Status (8)

Country Link
US (1) US20040142978A1 (pt)
EP (1) EP1569932A1 (pt)
JP (1) JP2006519760A (pt)
AU (1) AU2003299592A1 (pt)
BR (1) BR0317284A (pt)
CA (1) CA2509244A1 (pt)
MX (1) MXPA05006368A (pt)
WO (1) WO2004055015A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US7473694B2 (en) 2005-03-17 2009-01-06 Teijin Pharma Limited Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof
US7417053B2 (en) 2005-04-07 2008-08-26 Teijin Pharma Limited Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof
AU2006275403A1 (en) * 2005-08-02 2007-02-08 Lexicon Pharmaceuticals, Inc. 2-aminoaryl pyridines as protein kinases inhibitors
JPWO2009028543A1 (ja) * 2007-08-30 2010-12-02 武田薬品工業株式会社 置換ピラゾール誘導体
US8343966B2 (en) * 2008-01-11 2013-01-01 Novartis Ag Organic compounds
WO2010007756A1 (ja) * 2008-07-14 2010-01-21 塩野義製薬株式会社 Ｔｔｋ阻害作用を有するピリジン誘導体
FR2951172B1 (fr) * 2009-10-13 2014-09-26 Pf Medicament Derives pyrazolopyridines en tant qu'agent anticancereux
AU2011303597A1 (en) * 2010-09-17 2013-04-11 Purdue Pharma L.P. Pyridine compounds and the uses thereof
WO2013144191A1 (de) 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen
EP2951157A1 (en) * 2013-02-04 2015-12-09 Merck Patent GmbH Positive allosteric modulators of mglur3
CZ308052B6 (cs) * 2017-05-24 2019-11-20 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Polysubstituované pyrimidiny
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2023278564A1 (en) * 2021-07-02 2023-01-05 Mirati Therapeutics, Inc. Aminopyridine-based mta-cooperative prmt5 inhibitors
US11926595B1 (en) 2023-11-24 2024-03-12 King Faisal University 2-(2-ethoxyethoxy)-6-(4-hydroxyphenyl)-4-(4-methylphenyl)nicotinonitrile as an antimicrobial compound
US11970453B1 (en) 2023-11-28 2024-04-30 King Faisal University 2-ethoxy-8-(4-fluorobenzylidene)-4-(4-fluorophenyl)-5,6,7,8-tetrahydroquinoline-3-carbonitrile as an antimicrobial compound
US11970455B1 (en) 2023-12-08 2024-04-30 King Faisal University 7-(4-fluorobenzylidene)-4-(4-fluorophenyl)-2-methoxy-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile as an antimicrobial compound
US11932605B1 (en) 2023-12-12 2024-03-19 King Faisal University 9-(4-nitrobenzylidene)-4-(4-nitrophenyl)-3-cyano-2-methoxy-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridine as an antimicrobial compound
US12612369B1 (en) 2025-12-15 2026-04-28 King Faisal University Eco-friendly synthesis of a novel nicotinonitrile derivative (MNPN) with antibacterial and anti-inflammatory activities for preventing pressure ulcers in individuals with disabilities

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299963A (en) * 1977-03-08 1981-11-10 Takeda Chemical Industries, Ltd. 1-Azaxanthone derivatives
US5192768A (en) * 1990-09-14 1993-03-09 Kyowa Hakko Kogyo Co., Ltd. Pyrazoloquinoline derivatives
DE4039272A1 (de) * 1990-12-08 1992-06-11 Basf Ag Pyrido-anellierte 4-oxo-4h-benzopyrane, verfahren zu ihrer herstellung und ihre verwendung als antidots
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US6218136B1 (en) * 1996-03-12 2001-04-17 Smithkline Beecham Corporation Methods of the identification of pharmaceutically active compounds
ES2339196T3 (es) * 1997-07-18 2010-05-17 Novo Nordisk Health Care Ag Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente.
AU1924699A (en) * 1997-12-19 1999-07-12 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
HUP0301932A3 (en) * 2000-05-22 2007-09-28 Leo Pharma As Benzophenones as inhibitors of il-1 beta and tnf-alpha, pharmaceutical compositions containing them and use of them for producing pharmaceutical compositions

Also Published As

Publication number Publication date
US20040142978A1 (en) 2004-07-22
WO2004055015A1 (en) 2004-07-01
AU2003299592A1 (en) 2004-07-09
CA2509244A1 (en) 2004-07-01
EP1569932A1 (en) 2005-09-07
MXPA05006368A (es) 2006-02-08
AU2003299592A8 (en) 2004-07-09
JP2006519760A (ja) 2006-08-31

Similar Documents

Publication Publication Date Title
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
BRPI0412894A (pt) tienopiridina e furopiridina inibidores de quinases
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
BRPI0413973A (pt) compostos
BR0309556A (pt) Inibidores de metaloproteinase pirimidina-2,4,6-triona
BR0313420A (pt) Quinolonas microbicidas, suas composições e usos
BR0307833A (pt) Sìntese controlada de ziprasidona e suas composições
BRPI0413922A (pt) xantinas de 8-heteroarila substituìda
BR0308339A (pt) Indazóis substituìdos com uma atividade anticancerosa
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
DE60314623D1 (de) Substituierte pyrazolopyrimidine
BR0208338A (pt) Derivados de piridina
BRPI0418031A (pt) inibidores de quinase fosfonato-substituìdos
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
BR0305258A (pt) Inibidores de polimerase de ns5b de hcv
ATE479687T1 (de) Kinaseinhibitoren
BRPI0412659A (pt) isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BR0308211A (pt) Cumarinas úteis como biomarcadores
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
SV2004001555A (es) Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos
BRPI0418255A (pt) derivados de piperazina e piperidina n-substituìdos
BRPI0407841A (pt) inibidores heterocìclicos de quinase

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.